Differential Localization and Regulation of Death and Decoy Receptors for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Human Melanoma Cells1

Induction of apoptosis in cells by TNF-related apoptosis-inducing ligand (TRAIL), a member of the TNF family, is believed to be regulated by expression of two death-inducing and two inhibitory (decoy) receptors on the cell surface. In previous studies we found no correlation between expression of decoy receptors and susceptibility of human melanoma cells to TRAIL-induced apoptosis. In view of this, we studied the localization of the receptors in melanoma cells by confocal microscopy to better understand their function. We show that the death receptors TRAIL-R1 and R2 are located in the trans-Golgi network, whereas the inhibitory receptors TRAIL-R3 and -R4 are located in the nucleus. After exposure to TRAIL, TRAIL-R1 and -R2 are internalized into endosomes, whereas TRAIL-R3 and -R4 undergo relocation from the nucleus to the cytoplasm and cell membranes. This movement of decoy receptors was dependent on signals from TRAIL-R1 and -R2, as shown by blocking experiments with Abs to TRAIL-R1 and -R2. The location of TRAIL-R1, -R3, and -R4 in melanoma cells transfected with cDNA for these receptors was similar to that in nontransfected cells. Transfection of TRAIL-R3 and -R4 increased resistance of the melanoma lines to TRAIL-induced apoptosis even in melanoma lines that naturally expressed these receptors. These results indicate that abnormalities in “decoy” receptor location or function may contribute to sensitivity of melanoma to TRAIL-induced apoptosis and suggest that further studies are needed on the functional significance of their nuclear location and TRAIL-induced movement within cells.

[1]  V. Dixit,et al.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling , 1998, FEBS letters.

[2]  S. Jones,et al.  TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. , 1999, Journal of immunology.

[3]  S. Kjaer,et al.  Risk factors for HPV infection in women from sexually transmitted disease clinics: Comparison between two areas with different cervical cancer incidence , 1998, International journal of cancer.

[4]  J. Bell,et al.  Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. , 1998, Journal of immunology.

[5]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[6]  E. Coligan.  Current protocols in immunology , 1991 .

[7]  P. Hersey,et al.  Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. , 1999, Cancer research.

[8]  I. Herr,et al.  Inhibition of Nuclear Factor κB Activation Attenuates Apoptosis Resistance in Lymphoid Cells , 1998 .

[9]  P. Hersey,et al.  TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. , 1998, Journal of immunology.

[10]  J. Jaffrezou,et al.  Low Temperatures and Hypertonicity Do Not Block Cytokine-induced Stimulation of the Sphingomyelin Pathway but Inhibit Nuclear Factor-κB Activation (*) , 1995, The Journal of Biological Chemistry.

[11]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[12]  J P Luzio,et al.  Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. , 1998, Science.

[13]  L. Lincz.  Deciphering the apoptotic pathway: All roads lead to death , 1998, Immunology and cell biology.

[14]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[15]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[16]  B. Aggarwal,et al.  TNF induces internalization of the p60 receptor and shedding of the p80 receptor. , 1994, Journal of immunology.

[17]  Karsten Weis,et al.  Exportin 1 (Crm1p) Is an Essential Nuclear Export Factor , 1997, Cell.

[18]  M. Powers,et al.  Nuclear Export Receptors: From Importin to Exportin , 1997, Cell.

[19]  J. Tschopp,et al.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.

[20]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[21]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[22]  S. Sharrow,et al.  Analysis of Flow Cytometry Data , 1991, Current protocols in immunology.

[23]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[24]  P. Hersey,et al.  Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[26]  I. Virtanen,et al.  Subcellular compartmentalization of saccharide moieties in cultured normal and malignant cells , 1980, The Journal of cell biology.

[27]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[28]  P. Hersey,et al.  Expression of the co-stimulatory molecule CD40 on melanoma cells. , 1996, International journal of cancer.

[29]  P. Hersey,et al.  CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95) , 1998, International journal of cancer.

[30]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[31]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[32]  J. Sheridan,et al.  Identification of a ligand for the death-domain-containing receptor Apo3 , 1998, Current Biology.

[33]  A. Gurney,et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.

[34]  G. Banting,et al.  Perturbation of the morphology of the trans-Golgi network following Brefeldin A treatment: redistribution of a TGN-specific integral membrane protein, TGN38 , 1992, The Journal of cell biology.

[35]  E. Dietzsch,et al.  A HUMAN PERIPHERAL MEMBRANE PROTEIN ENCODED BY A GENE ON CHROMOSOME 6p12-22 CONTAINS EXTENSIVE COILED-COIL a-HELICAL DOMAINS AND A GRANIN MOTIF* , 1996 .

[36]  C. Smith,et al.  Functional analysis of TRAIL receptors using monoclonal antibodies. , 1999, Journal of immunology.

[37]  E. Dietzsch,et al.  Molecular Characterization of trans-Golgi p230 , 1996, The Journal of Biological Chemistry.

[38]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[39]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[40]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[41]  P. Hersey,et al.  Expression of the co‐stimulatory molecule CD40 on melanoma cells , 1996 .

[42]  E. Whitehorn,et al.  Receptor-mediated Endocytosis of CC-chemokines* , 1997, The Journal of Biological Chemistry.

[43]  J. Bell,et al.  TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL , 1997, Current Biology.

[44]  J. Tschopp,et al.  Characterization of two receptors for TRAIL. , 1997, FEBS letters.

[45]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.